Abbisko Cayman (HKSE:02256) Tax Expense: HK$66.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02256 Abbisko Cayman Ltd HKSE:02256
56 GF Score
Price HK$10.54
GF Value HK$12.30
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Abbisko Cayman Tax Expense?

Abbisko Cayman HKSE:02256 -2.95% 56 Tax Expense is HK$66.9 Mil as of Dec. 2025. GuruFocus rates HKSE:02256 with a GF Score™ of 56/100 and a GF Value™ of HK$12.30 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Abbisko Cayman's tax expense for the months ended in Dec. 2025 was HK$0.0 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$66.9 Mil.


Abbisko Cayman  (HKSE:02256) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Abbisko Cayman Tax Expense Related Terms


Abbisko Cayman Tax Expense Historical Data

* Premium members only.

The historical data trend for Abbisko Cayman's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbisko Cayman Tax Expense Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 53.09 67.62

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 84.72 -30.93 66.91 0.00
HKSE:02256
56GF Score
Abbisko Cayman Ltd HKSE:02256
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbisko Cayman Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$66.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of HK$66.9 Mil mean?
Abbisko Cayman (HKSE:02256) has a Tax Expense of HK$66.9 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Abbisko Cayman and its competitors.
Is Abbisko Cayman's Tax Expense too high?
Abbisko Cayman's current Tax Expense is HK$66.9 Mil. Overall, Abbisko Cayman has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's Tax Expense compare to VRTX and REGN?
Abbisko Cayman's Tax Expense of HK$66.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Abbisko Cayman and its competitors. Abbisko Cayman's current Tax Expense is HK$66.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (HKSE:02256) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$12.30, compared to a current price of HK$10.54 — trading 14.3% below its estimated fair value. The current Tax Expense is HK$66.9 Mil. Abbisko Cayman's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Abbisko Cayman (HKSE:02256), the current Tax Expense is HK$66.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbisko Cayman (HKSE:02256) Overvalued in 2026?

Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued. The current stock price of HK$10.54 is trading 14.3% below its estimated GF Value™ of HK$12.30. GuruFocus considers Abbisko Cayman to be Modestly Undervalued.

Key valuation signals for HKSE:02256:

  • Tax Expense: HK$66.9 Mil
  • GF Value™: HK$12.30 vs. price of HK$10.54 (14.3% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02256 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abbisko Cayman Business Description

Other Exchanges 8ZD:Germany
Address Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
56GF Score

Get the complete analysis for HKSE:02256

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$10.54
Price
HK$12.30
GF Value